Nature Communications (Dec 2021)
Tumor evolution selectively inactivates the core microRNA machinery for immune evasion
- Tian-Yu Song,
- Min Long,
- Hai-Xin Zhao,
- Miao-Wen Zou,
- Hong-Jie Fan,
- Yang Liu,
- Chen-Lu Geng,
- Min-Fang Song,
- Yu-Feng Liu,
- Jun-Yi Chen,
- Yu-Lin Yang,
- Wen-Rong Zhou,
- Da-Wei Huang,
- Bo Peng,
- Zhen-Gang Peng,
- Yong Cang
Affiliations
- Tian-Yu Song
- Gene Editing Center, School of Life Science and Technology, ShanghaiTech University
- Min Long
- Gene Editing Center, School of Life Science and Technology, ShanghaiTech University
- Hai-Xin Zhao
- Oncology and Immunology Unit, WuXi Biology, WuXi AppTec (Shanghai) Co, Ltd
- Miao-Wen Zou
- Gene Editing Center, School of Life Science and Technology, ShanghaiTech University
- Hong-Jie Fan
- Gene Editing Center, School of Life Science and Technology, ShanghaiTech University
- Yang Liu
- Gene Editing Center, School of Life Science and Technology, ShanghaiTech University
- Chen-Lu Geng
- Gene Editing Center, School of Life Science and Technology, ShanghaiTech University
- Min-Fang Song
- Gene Editing Center, School of Life Science and Technology, ShanghaiTech University
- Yu-Feng Liu
- Gene Editing Center, School of Life Science and Technology, ShanghaiTech University
- Jun-Yi Chen
- Gene Editing Center, School of Life Science and Technology, ShanghaiTech University
- Yu-Lin Yang
- Oncology and Immunology Unit, WuXi Biology, WuXi AppTec (Shanghai) Co, Ltd
- Wen-Rong Zhou
- Oncology and Immunology Unit, WuXi Biology, WuXi AppTec (Shanghai) Co, Ltd
- Da-Wei Huang
- Oncology and Immunology Unit, WuXi Biology, WuXi AppTec (Shanghai) Co, Ltd
- Bo Peng
- Gene Editing Center, School of Life Science and Technology, ShanghaiTech University
- Zhen-Gang Peng
- Oncology and Immunology Unit, WuXi Biology, WuXi AppTec (Shanghai) Co, Ltd
- Yong Cang
- Gene Editing Center, School of Life Science and Technology, ShanghaiTech University
- DOI
- https://doi.org/10.1038/s41467-021-27331-3
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 15
Abstract
Dysregulation of the microRNA machinery has crucial roles in cancer development. Here the authors show that inactivation of proteins involved in microRNA-mediated gene silencing, such as ANKRD52 or AGO2, confers resistance to T cell-mediated immune response in a preclinical cancer model.
